myriad genetics inc shares dropped roughly 18 to 1692 tuesday after the company lowered its fiscal 2022 guidance the molecular diagnostic tests company updated revenue guidance to between 668 million to 672 million and adjusted loss per share to between 30 cents to 35 cents the company previously forecast revenue between 670 million to 700 million and eps to between 0 cents to a loss of 10 cents a share on an adjusted basis myriad said the revised guidance reflects thirdquarter business updates the effect of currency translation and change of estimates excluding typical seasonality and other temporary headwinds we believe the overall strength of our business model and improving growth trajectory is clear said chief executive paul diaz the guidance comes after thirdquarter results showed lower revenue and swung to a loss myriad posted a loss of 351 million or 43 cents a share compared with net income of 246 million or 30 cents a share a year earlier adjusted loss per share was 19 cents analysts polled by factset expected an adjusted loss of four cents a share revenue declined to 1564 million from 1673 million analysts polled by factset expected 1701 million separately the company said it acquired personal genomics company gateway genomics llc for a cash purchase price of 675 million gateway could earn an additional 325 million of cash payments in 2023 and 2024 if certain financial targets are hit myriad said myriad said gateways business is expected to be accretive to its growth rate earnings and operating cash flows in 2024